¿Cómo se compara el ratio PS de CSII con empresas similares?

CSII es cara según su ratio Price-To-Sales (3.5x) en comparación con la media de empresas similares (3x).

¿Cómo se compara el ratio PS de CSII con el de otras empresas de la industria US Medical Equipment ?

CSII es un buen valor basado en su ratio Price-To-Sales (3.5x) comparado con la media de la industria US Medical Equipment (3.4x).

¿Cuál es el ratio PS de CSII comparado con su ratio PS justo? Este es el ratio PS esperado teniendo en cuenta las estimaciones de crecimiento de ingresos de la empresa, los márgenes de beneficios y otros factores de riesgo.

CSII es cara según su ratio Price-To-Sales (3.5x) comparado con el ratio justo estimado Price-To-Sales (3.2x).

¿Cuál es el precio justo de CSII si consideramos sus flujos de caja futuros? Para esta estimación utilizamos un modelo de flujo de caja descontado.

Datos insuficientes para calcular el valor justo de CSII para el análisis de valoración.

¿Cuál es la estimación de los analistas a 12 meses y, existe una confianza estadística en el precio objetivo de consenso?

El precio objetivo es inferior al 20% superior al precio actual de la acción.

Cardiovascular Systems (Nasdaq:CSII) - Cotización, noticias y análisis

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Resumen de acción CSII

Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally.

Acerca de la empresa

Análisis fundamental de CSII
Puntuación del snowflake
Valoración	1/6
Crecimiento futuro	1/6
Rendimiento pasado	0/6
Salud financiera	6/6
Dividendos	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 11.12%

Análisis de riesgos

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

Volatilidad del precio de la acción en los últimos 3 meses

Competidores de Cardiovascular Systems, Inc.

Paragon 28

NYSE:FNA

US$637.4m

Treace Medical Concepts

NasdaqGS:TMCI

US$516.4m

Varex Imaging

NasdaqGS:VREX

US$597.0m

Nevro

NYSE:NVRO

US$199.2m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Cardiovascular Systems
Precios históricos de las acciones
Precio actual de la acción	US$20.00
Máximo en las últimas 52 semanas	US$20.57
Mínimo de 52 semanas	US$12.26
Beta	0.74
1Cambio en 1 mes	0.70%
Variación en 3 meses	49.48%
Cambio de 1 año	1.63%
3Variación en 3 años	-52.38%
Variación en 5 años	-25.90%
Variación desde la OPV	123.46%

Noticias y actualizaciones recientes

We're Not Very Worried About Cardiovascular Systems' (NASDAQ:CSII) Cash Burn Rate

Feb 03

Recent updates

We're Not Very Worried About Cardiovascular Systems' (NASDAQ:CSII) Cash Burn Rate

Feb 03

We're Hopeful That Cardiovascular Systems (NASDAQ:CSII) Will Use Its Cash Wisely

Oct 12

Cardiovascular Systems reports Q4 earnings miss; provides FY23 revenue guidance in-line with estimates

Aug 03

Here's Why Cardiovascular Systems, Inc.'s (NASDAQ:CSII) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 05

Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 36%?

Oct 09

At US$36.59, Is It Time To Put Cardiovascular Systems, Inc. (NASDAQ:CSII) On Your Watch List?

Sep 18

Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 28%?

Jun 24

Is Now The Time To Look At Buying Cardiovascular Systems, Inc. (NASDAQ:CSII)?

Jun 03

We're Interested To See How Cardiovascular Systems (NASDAQ:CSII) Uses Its Cash Hoard To Grow

Apr 29

Should You Take Comfort From Insider Transactions At Cardiovascular Systems, Inc. (NASDAQ:CSII)?

Mar 17

Cardiovascular Systems (NASDAQ:CSII) Shareholders Have Enjoyed A Whopping 399% Share Price Gain

Feb 10

Cardiovascular Systems misses on revenue

Feb 03

Need To Know: Cardiovascular Systems, Inc. (NASDAQ:CSII) Insiders Have Been Selling Shares

Dec 11

Cardiovascular Systems, Inc. 2021 Q1 - Results - Earnings Call Presentation

Nov 06

Rentabilidad de los accionistas

	CSII	US Medical Equipment	Mercado US
7D	0.1%	1.2%	3.9%
1Y	1.6%	27.0%	33.2%

Rentabilidad vs. Industria: CSII superó a la industria US Medical Equipment, que obtuvo un rendimiento del 29.9% el año pasado.

Rentabilidad vs. Mercado: CSII superó al mercado US, que obtuvo un rendimiento del 36.9% el año pasado.

Volatilidad de los precios

Is CSII's price volatile compared to industry and market?
CSII volatility
CSII Average Weekly Movement	14.0%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de CSII ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CSII(14%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1989	725	Scott Ward	www.csi360.com

Resumen de fundamentos de Cardiovascular Systems, Inc.

¿Cómo se comparan los beneficios e ingresos de Cardiovascular Systems con su capitalización de mercado?
Estadísticas fundamentales de CSII
Capitalización bursátil	US$843.96m
Beneficios(TTM)	-US$37.87m
Ingresos (TTM)	US$239.84m

3.5x

Ratio precio-ventas (PS)

-22.3x

Ratio precio-beneficio (PE)

¿Está CSII sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CSII
Ingresos	US$239.84m
Coste de los ingresos	US$66.22m
Beneficio bruto	US$173.63m
Otros gastos	US$211.49m
Beneficios	-US$37.87m

Últimos beneficios comunicados

Dec 31, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.90
Margen bruto	72.39%
Margen de beneficio neto	-15.79%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado CSII a largo plazo?

Ver rendimiento histórico y comparativa

This company has been acquired

Resumen de acción CSII

Recompensas

Análisis de riesgos

Competidores de Cardiovascular Systems, Inc.

NYSE:FNA

US$637.4m

NasdaqGS:TMCI

US$516.4m

NasdaqGS:VREX

US$597.0m

NYSE:NVRO

US$199.2m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire Cardiovascular Systems, Inc. (NasdaqGS:CSII) for approximately $880 million.

We're Not Very Worried About Cardiovascular Systems' (NASDAQ:CSII) Cash Burn Rate

Cardiovascular Systems, Inc. to Report Q2, 2023 Results on Feb 09, 2023

Cardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical Study

Price target decreased to US$21.20

Recent updates

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire Cardiovascular Systems, Inc. (NasdaqGS:CSII) for approximately $880 million.

We're Not Very Worried About Cardiovascular Systems' (NASDAQ:CSII) Cash Burn Rate

Cardiovascular Systems, Inc. to Report Q2, 2023 Results on Feb 09, 2023

Cardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical Study

Price target decreased to US$21.20

Insufficient new directors

First quarter 2023 earnings: EPS misses analyst expectations

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Year Ending June 30, 2023

Cardiovascular Systems, Inc. Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems

Cardiovascular Systems, Inc. to Report Q1, 2023 Results on Nov 03, 2022

We're Hopeful That Cardiovascular Systems (NASDAQ:CSII) Will Use Its Cash Wisely

Cardiovascular Systems, Inc., Annual General Meeting, Nov 08, 2022

Full year 2022 earnings: EPS misses analyst expectations

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Year Ending June 30, 2023

Cardiovascular Systems reports Q4 earnings miss; provides FY23 revenue guidance in-line with estimates

Cardiovascular Systems, Inc. to Report Q4, 2022 Results on Aug 02, 2022

Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from Russell 2000 Growth-Defensive Index

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Price target decreased to US$23.50

Cardiovascular Systems, Inc. to Report Q3, 2022 Results on May 04, 2022

Cardiovascular Systems, Inc. Announces Ryan Egeland Employment Would End as Chief Medical Officer

Consensus revenue estimates fall by 10%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fiscal Year Ending June 30, 2022

Cardiovascular Systems, Inc. Along with Orbusneich Medical Company Ltd, Announces FDA PMA Approval of Orbusneich’s Scoreflex®NC Scoring Percutaneous Transluminal Coronary Angioplasty Catheter

Cardiovascular Systems, Inc. Announces Development of Intravascular Lithotripsy Technology for the Treatment of Coronary and Peripheral Artery Diseases

No longer forecast to breakeven

First quarter 2022 earnings released: US$0.22 loss per share (vs US$0.054 loss in 1Q 2021)

Price target decreased to US$41.50

Here's Why Cardiovascular Systems, Inc.'s (NASDAQ:CSII) CEO Compensation Is The Least Of Shareholders' Concerns

Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 36%?

Cardiovascular Systems, Inc. Announces First Patient Treated with ViperCross Peripheral Support Catheter

At US$36.59, Is It Time To Put Cardiovascular Systems, Inc. (NASDAQ:CSII) On Your Watch List?

Consensus forecasts updated

Consensus forecasts updated

Full year 2021 earnings released: US$0.35 loss per share (vs US$0.80 loss in FY 2020)

Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 28%?

Is Now The Time To Look At Buying Cardiovascular Systems, Inc. (NASDAQ:CSII)?

Cardiovascular Systems, Inc. Announces U.S. Commercial Launch of JADE Over-the-Wire Non-Compliant Peripheral Balloon Catheters

Cardiovascular Systems, Inc Announces Results from a Real-World Optical Coherence Tomography

Independent Director recently bought US$52k worth of stock

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fourth Quarter Ending June 30, 2021

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.085 loss in 3Q 2020)

We're Interested To See How Cardiovascular Systems (NASDAQ:CSII) Uses Its Cash Hoard To Grow

Cardiovascular Systems, Inc. Announces First Uses of WIRION® Embolic Protection System

Should You Take Comfort From Insider Transactions At Cardiovascular Systems, Inc. (NASDAQ:CSII)?

Cardiovascular Systems (NASDAQ:CSII) Shareholders Have Enjoyed A Whopping 399% Share Price Gain

First Patient in Europe Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System

Earnings beat expectations, revenue disappoints

Second quarter 2021 earnings released: US$0.001 loss per share (vs US$0.10 loss in 2Q 2020)

Cardiovascular Systems misses on revenue

Cardiovascular Systems, Inc. Announces Partnership with Chansu Vascular Techologies, Llc to Develop New Drug-Coated Balloon Technology

Cardiovascular Systems, Inc. Elects Sachin Jain as a Class II Director

New 90-day high: US$46.79

Cardiovascular Systems, Inc. to Report Q2, 2021 Results on Feb 03, 2021

New 90-day high: US$44.30